Document 0234
 DOCN  M95B0234
 TI    Enhancement by hydroxyurea of the anti-human immunodeficiency virus type
       1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood
       mononuclear cells.
 DT    9511
 AU    Gao WY; Mitsuya H; Driscoll JS; Johns DG; Experimental Retrovirology
       Section, NCI, National Institutes of; Health, Bethesda, MD 20982, USA.
 SO    Biochem Pharmacol. 1995 Jul 17;50(2):274-6. Unique Identifier : AIDSLINE
       MED/95358722
 AB    Ribonucleotide reductase inhibitors such as hydroxyurea (HU) and related
       compounds, at low, non-toxic doses, enhance the anti-human
       immunodeficiency virus type 1 (HIV-1) potency of both purine and
       pyrimidine 2',3'-dideoxynucleosides (ddNs) in human lymphocytes and
       macrophages. The most marked enhancement of inhibition of HIV-1
       replication reported to date has been seen with the purine ddN
       2',3'-dideoxyinosine (ddIno): a low level of HU (0.1 mM) permitted a
       4.5-fold reduction in optimal ddIno dosage with no decrease in
       therapeutic effect or increase in toxicity. We report here even more
       marked enhancement by HU of the potency of the purine ddN
       2'-beta-fluoro-2',3'-dideoxyadenosine (2'-beta-F-ddAdo), where the
       addition of 0.1 mM HU permitted a 7.1-fold reduction in the optimal dose
       of 2'-beta-F-ddAdo in the phytohemagglutinin-activated peripheral blood
       mononuclear cell HIV-1 test system.
 DE    Antiviral Agents/*PHARMACOLOGY  Cells, Cultured  Comparative Study
       Dideoxyadenosine/*ANALOGS & DERIVATIVES/PHARMACOLOGY  Drug Synergism
       Human  Hydroxyurea/*PHARMACOLOGY  HIV Core Protein p24/ANALYSIS
       HIV-1/*DRUG EFFECTS  Monocytes/*DRUG EFFECTS/VIROLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).